glp 1 dementia study The EVOKE trials found that semaglutide, the GLP-1 drug behind several popular diabetes and weight loss medications, did not meaningfully slow cognitive decline in people with Alzheimer's disease. Despite these findings, scientists How GLP-1s Could Transform Alzheimer's

Brancaccio, G

For type 2 diabetes, other medication classes such as metformin, SGLT2 inhibitors, or DPP-4 inhibitors may be appropriate alternatives

Releases WADAs 2026 Prohibited List is now in force The World Anti-Doping Agency (WADA) wishes to remind stakeholders that the 2026 List of Prohibited Substances and Methods (List) and the 2026 Monitoring Program are now in force as of today (1 January 2026)

T.BittermanK

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

[26] Leigh portrays Schwarzenegger as obsessed with power and quotes him as saying, "I wanted to be part of the small percentage of people who were leaders, not the large mass of followers